Market Research Reports, Inc.

MarketResearchReports.com: Cardiovascular Disease (CVD) Market Is Expected to Reach $18.2 Billion by 2019

Market Research Reports, Inc. has announced the addition of “Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 - Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat” research report to their offering.

 
Repost This

Lewes, DE -- (SBWIRE) -- 12/31/2013 -- The global market for Cardiovascular Disease (CVD) - comprised of Heart Failure (HF), Myocardial Infarction and Acute Coronary Syndrome (ACS) - is expected to grow at a moderate rate, from $13.7 billion in 2012 to $18.2 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 4.1%.

For more information please visit: http://www.marketresearchreports.com/gbi-research/cardiovascular-diseases-therapeutics-major-developed-markets-2019-increasing-prevalence

The latest report states that out of the eight major markets (the US, France, Germany, Italy, Spain, UK, Japan and Canada), the US will boast the largest value, from $6.1 billion in 2012 to $8.49 billion by 2019, at a higher CAGR of 4.7%.

This growth is partially due to the increase of the treatment population, which is forecast to jump from 14 million in 2012 to 16 million by 2019, at a CAGR of 1.6%.New drugs are also expected to have a positive impact upon the CVD market, including LCZ696 and Serelaxin by Novartis, AZD6140 by AstraZeneca and BAY81-8781 by Bayer.

Analyst of this report, says: “Over recent decades, a large amount of research and innovation has been incorporated in the cardiovascular therapeutics market segment. Of the whole pipeline, 37% of drugs are undergoing Phase II and Phase III trials. This indicates a strong pipeline capable of boosting the market in the coming years.”

However, the CVD market is hampered by high costs, with the annual cost of treatment for the three CVD indications estimated to increase from $4,214 in 2012 to $4,876 by 2019, at a CAGR of 2.1%.

“New therapy drugs, such as LCZ696 and Serelaxin by Novartis, are promising upcoming treatments that will be expensive due to their specificity. This will in turn consume a large share of patients’ healthcare expenditure, which is somewhat unavoidable,” the analyst concludes.

This report provides an in-depth analysis of the cardiovascular therapeutic indications, namely heart failure, myocardial infarction (MI), and acute coronary syndrome (ACS) in the eight major markets — the US, France, Germany, Italy, Spain, UK, Japan and Canada. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three cardiovascular indications.

Browse other market research reports in diseases at http://www.marketresearchreports.com/diseases

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Follow us on slideshare : http://www.slideshare.net/MarketResearchReports